Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers

Soo Yeon Hwang, Seojeong Park, Hyunji Jo, Seung Hee Seo, Kyung Hwa Jeon, Seojeong Kim, Ah Reum Jung, Chanju Song, Misun Ahn, Soo Yeon Kwak, Hwa Jong Lee, Motonari Uesugi, Younghwa Na, Youngjoo Kwon

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Introduction: HER2 overexpression induces cancer aggression and frequent recurrences in many solid tumors. Because HER2 overproduction is generally followed by gene amplification, inhibition of protein–protein interaction (PPI) between transcriptional factor ELF3 and its coactivator MED23 has been considered an effective but challenging strategy. Objectives: This study aimed to determine the hotspot of ELF3-MED23 PPI and further specify the essential residues and their key interactions in the hotspot which are controllable by small molecules with significant anticancer activity. Methods: Intensive biological evaluation methods including SEAP, fluorescence polarization, LC-MS/MS-based quantitative, biosensor, GST-pull down assays, and in silico structural analysis were performed to determine hotspot of ELF3-MED23 PPI and to elicit YK1, a novel small molecule PPI inhibitor. The effects of YK1 on possible PPIs of MED23 and the efficacy of trastuzumab were assessed using cell culture and tumor xenograft mouse models. Results: ELF3-MED23 PPI was found to be specifically dependent on H-bondings between D400, H449 of MED23 and W138, I140 of ELF3 for upregulating HER2 gene transcription. Employing YK1, we confirmed that interruption on these H-bondings significantly attenuated the HER2-mediated oncogenic signaling cascades and exhibited significant in vitro and in vivo anticancer activity against HER2-overexpressing breast and gastric cancers even in their trastuzumab refractory clones. Conclusion: Our approach to develop specific ELF3-MED23 PPI inhibitor without interfering other PPIs of MED23 can finally lead to successful development of a drug resistance-free compound to interrogate HER2 biology in diverse conditions of cancers overexpressing HER2.

Original languageEnglish
Pages (from-to)173-187
Number of pages15
JournalJournal of Advanced Research
StatePublished - May 2023

Bibliographical note

Publisher Copyright:
© 2023


  • ELF3-MED23 interaction
  • HER2 transcriptional downregulator
  • Hotspot identification
  • Small molecule PPI inhibitor
  • Trastuzumab resistance


Dive into the research topics of 'Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers'. Together they form a unique fingerprint.

Cite this